We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+10.71%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.54B
AUM Growth
+$321M
Cap. Flow
-$140M
Cap. Flow %
-5.5%
Top 10 Hldgs %
33.9%
Holding
112
New
21
Increased
26
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$105M
2
DBVT
DBV Technologies
DBVT
+$41.9M
3
LCI
Lannett Company, Inc.
LCI
+$30.8M
4
RVNC
Revance Therapeutics, Inc.
RVNC
+$28.7M
5
ELV icon
Elevance Health
ELV
+$27.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$79.5M
2
MCK icon
McKesson
MCK
+$49.5M
3
NXTM
NxStage Medical Inc.
NXTM
+$43.6M
4
VTRS icon
Viatris
VTRS
+$24.8M
5
PDCO
Patterson Companies, Inc.
PDCO
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 78.77%
2 Financials 0.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
51
Xencor
XNCR
$1.3B
$11.4M 0.45%
522,000
– –
APLS
52
DELISTED
Apellis Pharmaceuticals
APLS
$11.1M 0.44%
+513,000
New +$7.55M
WVE icon
53
Wave Life Sciences
WVE
$1.12B
$11M 0.43%
314,674
-265,326
-46% -$7.74M
RETA
54
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$11M 0.43%
390,000
+200,000
+105% +$5.58M
WBA
55
DELISTED
Walgreens Boots Alliance
WBA
$10.5M 0.41%
+145,000
New +$10.2M
ALPN
56
DELISTED
Alpine Immune Sciences Inc
ALPN
$10.2M 0.4%
913,100
-20,000
-2% -$218K
FPRX
57
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$9.88M 0.39%
+450,728
New +$14.5M
BHVN
58
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$9.2M 0.36%
341,000
+176,000
+107% +$4.85M
OPCH icon
59
Option Care Health
OPCH
$3.41B
$9.09M 0.36%
781,000
+504,208
+182% +$5.09M
RGNX icon
60
Regenxbio
RGNX
$534M
$8.52M 0.34%
+256,300
New +$7.72M
SYBX
61
DELISTED
Synlogic
SYBX
$8.25M 0.32%
56,676
– –
ALIM
62
DELISTED
Alimera Sciences
ALIM
$8.05M 0.32%
403,529
– –
DCPH
63
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$7.62M 0.3%
336,009
+11,009
+3% +$216K
NEOS
64
DELISTED
Neos Therapeutics, Inc
NEOS
$7.61M 0.3%
745,767
-823,154
-52% -$7.9M
IVTY
65
DELISTED
Invuity, Inc
IVTY
$7.3M 0.29%
1,177,229
– –
MRTX
66
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.84M 0.27%
+375,000
New +$5.82M
MCK icon
67
CALL
McKesson
MCK
$98.5B
$6.74M 0.27%
43,200
– –
SRRA
68
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$6.57M 0.26%
44,027
-25,973
-37% -$2.5M
ALNA
69
DELISTED
Allena Pharmaceuticals
ALNA
$6.09M 0.24%
+605,100
New +$7.46M
STDY
70
DELISTED
SteadyMed Ltd
STDY
$5.25M 0.21%
1,418,787
– –
PTGX icon
71
Protagonist Therapeutics
PTGX
$9.06B
$4.68M 0.18%
+225,000
New +$3.99M
EIGR
72
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.18M 0.16%
+10,000
New +$3.57M
IFRX icon
73
InflaRx
IFRX
$273M
$3.67M 0.14%
+175,000
New +$3.16M
TSRO
74
DELISTED
TESARO, Inc.
TSRO
$3.56M 0.14%
+42,893
New +$4.21M
FOMX
75
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.01M 0.12%
501,000
-316,435
-39% -$1.9M
1 2
3
4

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2017 Portfolio in Review

As of Q4 2017, Deerfield Management held 112 positions worth $2.54B, up 14% from $2.22B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Deerfield Management withdrew a net $140M in Q4 2017, closing 14 positions and reducing 21 holdings. Its most notable exit was NxStage Medical Inc., an estimated $43.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 76% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Revance Therapeutics, Inc. worth $35.8M.

  • Deerfield Management's largest Q4 2017 buy was Revance Therapeutics, Inc.: 1,000,000 shares worth $35.8M.
  • Deerfield Management added most to MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2017, an estimated $105M increase.
  • Deerfield Management's biggest Q4 2017 reduction was AveXis, Inc. Common Stock, cutting an estimated $79.5M.
  • Deerfield Management fully exited NxStage Medical Inc. in Q4 2017, selling an estimated $43.6M.
  • Deerfield Management's ten largest holdings make up 34% of its $2.54B portfolio in Q4 2017.
  • Deerfield Management opened 21 new positions and closed 14 in Q4 2017.
  • Deerfield Management's portfolio value rose 14% quarter-over-quarter to $2.54B.

Based on Deerfield Management's 13F filing for Q4 2017, filed 14 Feb 2018.